Entrada Therapeutics (TRDA) Net Margin (2023 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Net Margin of 4539.09% for Q1 2026, down 445470.0% year-over-year from N/an in Q1 2025, and down 50.52% quarter-over-quarter from 3015.55% in Q4 2025.
Powered by 
Analysis
Entrada Therapeutics (TRDA) Net Margin (2023 - 2026) Analysis & Trends
Entrada Therapeutics' Net Margin history runs 4 years deep, the most recent figure standing at 4539.09% for Q1 2026.
- In Q1 2026, Net Margin fell 445470.0% year-over-year to 4539.09%; the TTM figure through Mar 2026 stood at 2895.57% (down 290994.0% YoY), while the FY2025 annual figure was 565.38%, down 59652.0% from the prior year.
- Net Margin for Q1 2026 stood at 4539.09%, down from 3015.55% in the prior quarter.
- The five-year high for Net Margin was 81.09% in Q3 2023, with the low at 4539.09% in Q1 2026.
- The 4-year median for Net Margin is 71.7% (2024), against an average of 974.36%.
- The sharpest annual moves came in 2024 and 2026: Net Margin surged 20077 bps in 2024, then plunged 445470 bps in 2026.
- Entrada Therapeutics' Net Margin stood at 22.71% in 2023, then soared by 113 bps to 3.02% in 2024, then sank by 99813 bps to 3015.55% in 2025, then sank by 51 bps to 4539.09% in 2026.
- Business Quant data shows TRDA's Net Margin at 4539.09% in Q1 2026, 3015.55% in Q4 2025, and 2734.45% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Entrada Therapeutics | 297.03 Mn | 297.03 Mn | - | -4,762.03% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4,762.03% |
| Mar 31, 2026 | -4,539.09% |
| Dec 31, 2025 | -3,014.93% |
| Sep 30, 2025 | -2,737.30% |
| Jun 30, 2025 | -2,210.41% |
| Mar 31, 2025 | -84.39% |
| Dec 31, 2024 | 2.95% |
| Sep 30, 2024 | -71.50% |
| Jun 30, 2024 | 58.07% |
| Mar 31, 2024 | 39.74% |
| Dec 31, 2023 | -22.70% |
| Sep 30, 2023 | 81.09% |
| Jun 30, 2023 | -142.70% |
| Mar 31, 2023 | -26.62% |